The BCR-ABL oncoprotein exhibits deregulated protein tyrosine kinase activity and is implicated in the pathogenesis of Philadelphia chromosome (Ph)-positive human leukemias. Here, we report that ectopic expression of p210 BCR-ABL in the megakaryoblastic Mo7e cell line and in primary human CD34 
Introduction
The BCR-ABL oncogene is a fusion gene that characterizes the neoplastic clone of patients with chronic myeloid leukemia (CML). 1 It encodes a 210 kDa oncoprotein (p210 BCR-ABL ) 2 with constitutive tyrosine kinase activity. 3 CML has a triphasic clinical course with a chronic phase followed by an accelerated phase and then a terminal phase, known as blastic crisis, in which myeloid or lymphoid blasts fail to differentiate. In the chronic phase, one of the major biological abnormalities is an increased production of morphologically mature granulocytes. 4 This phase is also characterized by an abnormal, unregulated expansion of Philadelphia chromosome-positive (Ph þ ) primitive erythroid progenitors, both in bone marrow and in peripheral blood. 5 In addition, occasional examples of Ph þ patients presenting with an erythrocytosis have been reported. 6 Further evidence for an abnormal erythroid differentiation is suggested by an unexpectedly frequent occurrence of blast cells with erythropoietic and/or megakaryocytic surface determinants in non-lymphoid blast crises. 4 Moreover, most cell lines established from CML blast crisis patients exhibit some erythroid and/ or megakaryocytic characters. [7] [8] [9] These results strongly point to a critical role of BCR-ABL in acting upon erythroid and/or megakaryocytic development. p210 BCR-ABL perturbs many intracellular signaling pathways involved in cell proliferation, inhibition of apoptosis and adhesion, partly via protein-protein interactions and partly via tyrosine phosphorylation of target substrates. 10 BCR-ABL may also regulate the expression of proteins that are involved in lineage commitment and differentiation. 11, 12 These effects may explain previous observations showing that, by analogy with v-raf or Emu-myc, p210
BCR-ABL may alter cell fate to another lineage in several systems. Overexpression studies have shown that most cells transduced with BCR-ABL acquire an erythroid or myeloid phenotype. 13 BCR-ABL initiates an erythroid program in myeloid leukemic HL-60 cells 14 or induces a reversible block in the granulocytic program of differentiation in 32D cells. 15 In addition, mice engrafted with bone marrow cells infected with a BCR-ABL-encoding retrovirus develop multiple hematopoietic disorders, including a clonal hyperproliferation of erythroid and/ or mast cells. 13, 16, 17 Moreover, erythroid cells are generated from human cord blood CD34 þ -derived granulopoietic progenitors transduced with p210 BCR-ABL . 18 The precise molecular mechanisms that sustain the effect of p210 BCR-ABL on cell fate lineage remain poorly understood.
During the hierarchical development of myelopoiesis, a close developmental relationship exists between the erythroid and the megakaryocytic (MK) lineages, 19 as demonstrated by the identification of a bipotent BFU-E/MK progenitor in the mouse 20, 21 and human bone marrow. 22, 23 Furthermore, as revealed by gene targeting studies in mice, the development and differentiation of the erythroid and MK lineages are controlled by common transcription factors. [24] [25] [26] Among these transcription factors, FLI-1 (Friend leukemia integration 1) plays an essential role in both erythropoiesis and megakaryopoiesis. 27 In the present study, we report a novel mechanism whereby BCR-ABL overexpressing cells may undergo abnormal differentiation. p210
BCR-ABL expression in the Mo7e megakaryoblastic cell line and in human primary CD34 þ progenitors leads to erythroid differentiation at the expense of MK differentiation in both cell systems. This lineage reprogramming is associated with FLI-1 downregulation at the transcriptional level. These results suggest that BCR-ABL may interfere with lineage commitment and may directly deregulate differentiation.
Materials and methods

Purification of CD34
þ progenitors, cell lines and culture conditions Mo7e, transduced-Mo7e cells and 293-EBNA cells were cultured as described. 28 CD34 þ cells were isolated from apheresis products of mobilized individuals and cultured in serum-free medium supplemented with recombinant human (rh) fetal liver tyrosine kinase 3 ligand (rhFLT3L, 10 ng/ml), rh thrombopoietin (rhTPO), rhIL-3 and stem cell factor (rhSCF). 29 E/MK medium allowing erythroid and MK differentiation was the same cytokine-supplemented medium in which rh erythropoietin (rhEPO) (1 U/ml) was added. Cytokines were obtained from Amgen Corp (Thousand Oaks, CA, USA), except for rhTPO, provided by Kirin Brewery (Tokyo, Japan).
Antibodies and flow cytometry
Phycoerythrin (PE)-conjugated anti-CD31, anti-CD42 and anti-GPA; allophycocyanin (APC)-conjugated anti-CD41; PE-and APC-conjugated IgG1 and IgG2a control MoAbs were from BD Biosciences (Le Pont de Claix, France). After staining, cells were analyzed on a FACsort with the Cell Quest software package or sorted on a FacsDIVA flow cytometer equipped with an automatic cell deposition unit (BD Biosciences, Becton Dickinson Biosciences, Le pont de Claix, France).
Constructs and retrovirus production
BCR-ABL and the MSCV-Neop210 BCR-ABL retrovirus were as described. 28 FLI-1 cDNA from the pCS3-FLI-1 plasmid (gift from F. Moreau-Gachelin, INSERM U580, Paris, France) was subcloned into the MIGR1-empty (FLI-1-GFP) retroviral vector. VSV-G pseudotyped retroviruses were produced and titrated as described. 29 Titers ranged from 1 to 5 Â 10 6 infectious particles/ml. 
Retroviral transduction
Single-cell cloning and progeny analysis
One day after transduction, the GFP þ CD41 þ CD42 À cells were sorted at one cell/well into 96-well-plate and cultured under E/ MK condition. One week later, the differentiation of the progeny from each individual clone was monitored by morphology. Four different types of clones were observed: pure MK colonies containing 4-30 MKs and raising from MK progenitors, clones containing 1-3 MKs deriving from promegakaryoblasts (pro-MK) with little potency for division, pure erythroid clones and mixed erythro/MK clones. Wells containing numerous homogenous small cells were cytospun and stained with benzidine to ascertain their erythroid nature. Suspicious MK clones were ascertained by CD41 staining and flow cytometry analysis.
Microarrays
Five days after transduction with either control-GFP or p210 BCR-ABL -GFP viruses, GFP þ Mo7e cells were sorted and total RNA from each sample and from the parental Mo7e cells (used as reference) was extracted using the SV total RNA isolation system (Promega Co., Madison, WY, USA). cDNA labeling, hybridization and data analyses were as described, 30 using oligonucleotide microarrays (oligos longs 22K Agilent Technologies, Palo Alto, CA, USA). The ratio of the two fluorescence intensities (from the sample and from the reference) provided a quantitative measurement of the relative gene modulation.
Data availability
Data obtained from the microarray analysis have been submitted to Array Express at the European Bioinformatics Institute (http://www.ebi.ac.uk/arrayexpress/) (accession number E-TABM-173). Array Express is a public repository for microarray data aimed at storing well-annotated data in accordance with 'Microarray Gene Expression Data' recommendations (http://www.mged.org).
Real-time reverse transcription-PCR (RT-PCR) analysis
Primers and internal probes for FLI-1 amplification were as follows:
0 . For each fraction, the expression level of FLI-1 was expressed relative to b-actin (Perkin-Elmer).
Single-cell RT-PCR analysis
One day after transduction in the presence of imatinib or DMSO, the GFP þ CD41 þ CD42 À cells were single cell sorted. cDNAs were directly synthesized in each well. Each RT product was divided into eight wells before performing nested PCR as described previously. 31 
Western blotting
Protein levels of BCR-ABL or phosphotyrosine were determined as described. 28 FLI-1 and b-actin were revealed with an anti-FLI-1 (sc-356; Santa Cruz Biotechnology, Santa Cruz, CA, USA) or an anti-b-actin mouse (Sigma) antibody, respectively.
Statistics
Results of experimental points obtained from multiple experiments were reported as the mean 7s.d.
Results
BCR-ABL downregulates MK cell surface markers in Mo7e cells
The Mo7e cell line was derived from the transformation of an MK progenitor and expresses antigen determinants specific to bipotent erythro/MK precursors and to MK cells as well as antigen determinants common to multilineages. Mo7e cells were transduced with MIGR vectors, encoding either GFP alone or p210
BCR-ABL and GFP. 28 The phenotype of these Figures 1c and b) . Conversely, but later on at day 10 after transduction, the percentage of Mo7e p210 BCR-ABL -GFP þ cells stained for the erythroid marker glycophorin A and, even more strikingly, the MFI of this marker were significantly increased. Similar increases in the expression of the other erythroid markers CD36 and CD71 were also observed (data not shown). Interestingly, the downregulation of CD31 and CD42 was observed 24 h after the first exposure of the cells to p210 BCR-ABL retrovirus, suggesting that a cell selection is not responsible for this effect. No change in cell surface markers was detected when Mo7e cells were transduced with a retrovirus encoding a kinase-inactive BCR-ABL mutant, indicating that the p210 BCR-ABL -specific kinase activity was necessary to mediate its effect on the MK phenotype (data not shown).
p210 BCR-ABL induces erythroid differentiation to the detriment of MK differentiation in MK progenitors
To determine the effect of p210 BCR-ABL on erythroid differentiation in primary MK progenitors, CD34
þ cells were transduced with the p210 BCR-ABL -GFP or control-GFP retroviruses, grown for 4 days under E/MK condition culture and phenotyped by flow cytometry. The percentage of cells stained for MK markers (CD31, CD41, CD42) was significantly decreased in the GFP þ -p210 BCR-ABL -transduced cells compared to GFP þ -control cells, whereas the percentage of GFP þ cells expressing GPA was markedly increased in the p210 BCR-ABL -transduced cells (Figures  2a and b) . Similar results were observed when cells were stained with the anti-CD36 antibody (data not shown). These changes in the expression of MK and erythroid markers are associated with marked morphological modifications, as evidenced by May-Grü nwald Giemsa staining of sorted control-GFP þ or p210
To determine whether the p210 BCR-ABL effect was due to an instructive role of the oncoprotein on the erythroid commitment or to the promotion of a proliferative advantage to committed erythroid progenitors, we performed single-cell progeny analyses of CD34 þ CD41 þ CD42 À cell populations in association with the p210 BCR-ABL kinase inhibitor imatinib. 32 As shown in Figure 3a , addition of imatinib completely abolished p210 BCR-ABL kinase activity in CD34 þ cells transduced with p210 BCR-ABL -GFP. The GFP þ CD41 þ CD42 À cell population, highly enriched in MK progenitors, was sorted after transduction, seeded at one cell per well in the presence of imatinib or DMSO (Figure 3b ). In each of the three repeated experiments, the cloning efficiency was reproductively around 85% at day 7 in both the control and p210 BCR-ABL groups and the presence of imatinib only slightly reduced it (around 75%) in both groups. The lineage differentiation of at least 100 individual clones in each experiment and for each culture conditions was monitored by morphology, immunostaining, and erythroid maturation was further ascertained by benzidine coloration. In experiments performed with the GFP þ CD41 þ CD42 À population transduced with the control virus, 1170.5% of the wells contained pure erythroid cells (ascertained by benzidine coloration), 5271% contained numerous MKs originating from MK progenitors, 3670.5% contained a few MK deriving from a pro-MK, but no mixed erythroid/MK clones were seen (Figure 3c ). The addition of imatinib did not modify the overall repartition of erythroid and MK clones. In contrast, the GFP þ CD41 þ CD42 À population transduced with the p210 BCR-ABL -expressing virus gave rise to 42713% of the wells containing pure erythroid cells (fourfold increase, P ¼ 0.02), 1277% containing a great number of MKs (fourfold decrease, P ¼ 0.03), 3577% deriving from pro-MKs and 11711% of the wells containing mixed erythro/MK clones. The presence of imatinib in p210 BCR-ABL culture restored the proportion of erythroid and MK clones to a level comparable to control-GFP-transduced cells.
These single-cell experiments conclusively demonstrate that p210 BCR-ABL modifies the lineage output of individual cells belonging to the purified CD41 þ CD42 À cell population and thus strongly argues for a change in lineage programming, occurring at the level of both bipotent progenitors and MK-committed cells. However, these experiments do not formally exclude that some of these changes may be due to the selective outgrowth of CD41 þ CD42 À erythroid progenitors occurring during the 3 days transduction protocol. To address this question, we performed the same experiments with imatinib added only during the transduction procedure and removed after cell sorting for time culture. As observed previously, a significant decrease in colonies deriving from MK progenitors was seen (32717.2% versus 5177% in the continuous presence of imatinib, Po0.001), whereas the percentage of pure erythroid clones was still significantly increased (2175.4% versus 875.7% in the continuous presence of imatinib, Po0.015) and the frequency of clones arising from pro-MK was not statistically modified. Altogether, these single-cell experiments strongly argue for a modulation mediated by the kinase activity of p210 BCR-ABL on lineage programming and likely occurring both at the level of bipotent E/MK progenitors and MK-committed cells.
Gene expression profiling reveals upregulation of erythroid-specific genes and downregulation of MK-specific transcription genes
To investigate which target genes were modulated by p210 BCR-ABL , the profiles of transcripts of Mo7e cells transduced with control-or p210 BCR-ABL -GFP viruses were compared using microarrays. Microarray data were analyzed using the Rosetta Resolver software to identify the genes significantly modulated by p210 BCR-ABL (Po0.05) after exclusion of genes giving a very low intensity (less than 200). Our analysis was focused on about 300 hematopoietic genes related to the erythroid, and MK lineages, and genes whose expression was modified between control-GFP þ and p210 BCR-ABL -GFP þ cells are presented in Table I given as Supplementary Data 1. In p210 BCR-ABL -GFP þ cells, transcripts of genes highly expressed during MK differentiation, such as c-mpl, a-6 integrin, glycoproteins IX, platelet factor 4 and thromboxane A synthase, were significantly reduced, whereas various genes involved in erythropoiesis, such as erythrocyte membrane proteins or globin chains, were upregulated. In addition, transcripts of several transcription factors controlling erythroid and/or MK differentiation were also modulated (microarray analysis, accession number E-TABM-173). Changes in gene expression were validated by real-time RT-PCR, only 3 days after transduction. In three independent experiments, the expression levels of the hematopoietic transcription factors, p45 NF-E2, EKLF and GATA-1, were upregulated (3-, 6-and 13-fold, respectively; Supplementary Data 2) whereas FLI-1 was downregulated 15-fold in p210
BCR-ABL -GFP þ cells (Figure 4a ). In addition, the FLI-1 proteins were significantly decreased by p210 BCR-ABL (Figure 4b ). Altogether, the results confirm that expression of p210 BCR-ABL in the megakaryoblastic Mo7e cell line upregulates several genes known to be involved in erythropoietic differentiation and downregulates several genes known to be involved in megakaryocytic differentiation.
Enforced FLI-1 expression in p210 BCR-ABL -Mo7e cells restores expression of MK markers
Since FLI-1 expression appears to be required for MK development, 33, 34 we postulated that the erythroid switch induced by 
Discussion
Cumulative evidence supports the notion that BCR-ABL may interfere with differentiation. [13] [14] [15] [16] [17] [18] In this study, we show that the human megakaryocytic Mo7e cell line, as well as primary MK progenitor cells switched from MK to erythroid character after transduction with a p210 BCR-ABL -expressing retrovirus. Using a gene array strategy, we identify a strong downregulation of the FLI-1 transcription factor mediated by the kinase activity of p210 BCR-ABL , which was associated with erythroid lineage switching. Finally, we show that enforced re-expression of FLI-1 in p210 BCR-ABL -expressing cells may rescue the MK phenotype.
In both Mo7e and primary progenitors, the increased expression of erythroid markers induced by p210 BCR-ABL occurred at the expense of the expression of megakaryocytic markers. This opposite regulation of erythrocytic and megakaryocytic markers raised the intriguing possibility that enforced expression of p210 BCR-ABL might be able to reprogram MK progenitors toward erythroid differentiation. We addressed this question by the analysis of the single-cell progeny of a CD41
þ CD42 À population sorted immediately after the 3 days transduction protocol and these have been shown to be highly enriched in MK progenitors. Even in this CD41 þ CD42 À -purified population, our results showed an increased number of pure erythroid clones and a concomitant decreased number of MK clones derived from MK progenitors (Figure 3c ). However, although highly enriched in MK progenitors, this CD41 þ CD42
À population still contains erythroid progenitors, as indicated by the 10% of pure erythroid clones observed in our single-cell progeny analysis of the CD41 þ CD42 À population transduced by the control GFP virus (Figure 3c ). These single-cell experiments thus could not exclude that the increased number of erythroid clones might be derived from the selective outgrowth of these erythroid progenitors during the 3 days transduction protocol. Having shown that the switching effect of p210 BCR-ABL is completely suppressed by Imatinib (Figure 3c ), we took advantage of the reversibility of the effect of Imatinib to repress the p210 BCR-ABL kinase during the 3 days transduction period and to investigate the effect of de-repressing the kinase activity only after single-cell sorting of the transduced CD41 þ CD42 À population. Even under these conditions, we still observed a significant increase in the number of pure erythroid clones and a significant decrease in the number of MK clones derived from MK progenitors. These data unambiguously demonstrate that enforced expression of p210 BCR-ABL is indeed able to reprogram at least some already-committed MK progenitors present in the CD41 þ CD42 À population. Interestingly, this reprogramming seems to be limited only to early MK progenitors (and most probably also to bipotent progenitors), since the proportion of clones harboring few MK (MK clones from pro-MK) was never seen to be modified in the transduced CD41 þ CD42 À population (Figure 3c ). A gene array strategy using parental and p210 BCR-ABL overexpressing Mo7e cells revealed that several transcription factors shared during erythroid and MK differentiation were regulated by p210
BCR-ABL . Among these, FLI-1 and EKLF, which are more specific to the MK and erythroid lineages, were found to be down-or upregulated by p210 BCR-ABL , respectively. We focused our work on FLI-1 as this transcription factor in association with the fact that GATA-1 activates the transcription of several MKrestricted genes such as gpIX (CD42a), gpIba (CD42b), and c-mpl through cooperative DNA binding. [35] [36] [37] FLI-1 has also the ability to inhibit the erythroid differentiation in several erythroleukemic cell lines. [38] [39] [40] Altogether, these data strongly suggest that during normal hematopoiesis, FLI-1 not only activates the MK differentiation program but also simultaneously represses the erythroid program. In favor of this hypothesis, it was recently reported that FLI-1 knock-out induces a blockage in MK differentiation 33, 34, 41 with an expansion of erythroid progenitors. 42 A relationship between FLI-1 and p210 BCR-ABL is also suggested by the observation that the CML derived erythroleukemic K562 cell is deficient in FLI-1. Re-expression of FLI-1 in K562 cells induces an MK differentiation 36, 43 and inhibits the erythroid phenotype. 38 Similarly, our results show that when FLI-1 expression was enforced in p210 BCR-ABL -Mo7e cells, the cell line recovered its initial MK phenotype, demonstrating that FLI-1 was a key transcription factor responsible for the lineage switch induced by p210 BCR-ABL . Together, these data strongly suggest that the signaling pathway induced by p210 BCR-ABL is able to suppress or activate some transcription or repressor factors involved in the regulation of the erythro/MK commitment. Further experiments involving FLI-1 knockdown will be required to investigate whether FLI-1 downregulation is a direct consequence of BCR-ABL expression or a secondary effect. A similar regulation of transcription factors by p210 BCR-ABL has been reported previously. For example, p210 BCR-ABL is able to downregulate the transcript levels of the granulocyte colony stimulating factor receptor (G-CSFR) by inhibiting the translation of the transcription regulator C/EBPalpha, through hnRNP E2. 11 More recently, it has been shown that BCR-ABL induces an aberrant splicing of IKAROS, suggesting that BCR-ABL may interfere with lineage commitment. 12 In favor of this hypothesis, we have shown that FLI-1 expression was downregulated in Mo7e and in primary human hematopoietic cell by p210 BCR-ABL . Investigation of this novel transdifferentiation response offers insights into the normal mechanisms of lineage restriction and commitment in primitive human cells.
It remains to determine if the downregulation of FLI-1 expression by p210 BCR-ABL is relevant to the progression of the disease and to the lineage infidelity of the leukemic blasts frequently found in this disease. The downregulation of FLI-1 may participate to the frequency of erythroid markers on the blasts in CML. 9 It has been reported that CML patients have elevated numbers of erythroid progenitor cells. 44, 45 The present findings showing an upregulation of the generation of erythroid cells in the presence of p210 BCR-ABL are in line with the pathologic features of human CML. However, differentiation beyond the CFU-E stage is blocked in CML and many patients have some degree of anemia, supporting the hypothesis of a discordant maturation of erythroid progenitors in addition to an erythroid progenitor amplification described by the present and previous studies. 5, 18, 44, 46, 47 Finally, another important aspect in this study is the lineage switch was induced by an oncoprotein that is essentially a signaling molecule. Indeed, no effect on the lineage choice or on FLI-1 expression was found with a kinase-dead p210 BCR-ABL or when imatinib was added to culture, suggesting that kinase activity of p210 BCR-ABL is necessary to induce these effects. Whether other protein kinases that activate similar signaling pathway induce similar effects on E/MK commitment remains to be determined, but seem likely. In addition, the use of different p210 BCR-ABL mutant proteins or pharmacologic inhibitors may help to link signaling pathway to transcription factor regulation.
